Compare COHU & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | VRDN |
|---|---|---|
| Founded | 1947 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1994 | 2014 |
| Metric | COHU | VRDN |
|---|---|---|
| Price | $64.47 | $17.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $40.50 | $35.46 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $452,956,000.00 | $5,706,000.00 |
| Revenue This Year | $14.38 | $13.73 |
| Revenue Next Year | $19.12 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.74 | N/A |
| 52 Week Low | $17.80 | $13.18 |
| 52 Week High | $70.92 | $34.29 |
| Indicator | COHU | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 55.18 |
| Support Level | $20.99 | $15.58 |
| Resistance Level | N/A | $18.05 |
| Average True Range (ATR) | 3.90 | 0.78 |
| MACD | 0.83 | 0.15 |
| Stochastic Oscillator | 68.04 | 66.79 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads, and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection). Geographically, the company generates maximum revenue from the Philippines, followed by Taiwan, China, Malaysia, the United States, Singapore, and the Rest of the world.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.